1. Home
  2. CLPT vs FULC Comparison

CLPT vs FULC Comparison

Compare CLPT & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ClearPoint Neuro Inc.

CLPT

ClearPoint Neuro Inc.

HOLD

Current Price

$18.58

Market Cap

554.2M

Sector

Health Care

ML Signal

HOLD

Logo Fulcrum Therapeutics Inc.

FULC

Fulcrum Therapeutics Inc.

HOLD

Current Price

$3.74

Market Cap

467.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CLPT
FULC
Founded
1998
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
554.2M
467.8M
IPO Year
2009
2019

Fundamental Metrics

Financial Performance
Metric
CLPT
FULC
Price
$18.58
$3.74
Analyst Decision
Strong Buy
Buy
Analyst Count
1
8
Target Price
$20.00
$16.38
AVG Volume (30 Days)
892.4K
3.6M
Earning Date
05-13-2026
04-27-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$36,971,000.00
N/A
Revenue This Year
$45.67
N/A
Revenue Next Year
$19.51
N/A
P/E Ratio
N/A
N/A
Revenue Growth
17.78
N/A
52 Week Low
$8.27
$2.83
52 Week High
$30.10
$15.74

Technical Indicators

Market Signals
Indicator
CLPT
FULC
Relative Strength Index (RSI) 66.53 40.36
Support Level $12.55 $2.83
Resistance Level $27.64 $4.02
Average True Range (ATR) 1.47 0.22
MACD 0.17 0.14
Stochastic Oscillator 86.13 70.09

Price Performance

Historical Comparison
CLPT
FULC

About CLPT ClearPoint Neuro Inc.

ClearPoint Neuro Inc is a commercial-stage medical device company that develops and commercializes integrated systems used in minimally invasive neurosurgical procedures in the brain. The company's business consists of two integrated components: a business providing medical devices for neurosurgical applications, and a business focused on partnerships in the biologics and drug delivery space. The Company operates in one reportable segment.

About FULC Fulcrum Therapeutics Inc.

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.

Share on Social Networks: